Diagnostic accuracy of a novel blood (1→3)-β-D-glucan colourimetric assay for invasive fungal diseases: The β-glucan single M30 test WAKO
Medical Mycology · 2025
DOI: 10.1093/mmy/myaf105 ↗Kurz gefasst
Evaluationsstudie in der Zeitschrift Medical Mycology, 2025. Verfasst von Yasuhiro Tsuchido und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory Medicine, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan. Hauptthemen laut MEDLINE: beta-Glucans, Invasive Fungal Infections, Colorimetry. Die Arbeit nennt 35 Literaturangaben. Gefördert von: Fujifilm Wako Pure Chemical Corporation.
Abstract (Originalsprache)
Invasive fungal diseases (IFDs) are a major cause of morbidity and mortality in immunocompromised patients. (1→3)-β-D-glucan (BDG) is a fungus-derived biomarker used for IFD diagnosis. We aimed to evaluate the diagnostic performance of a novel rapid colourimetric assay, the β-glucan single M30 test WAKO (M30), and compare its performance with the conventional turbidimetric β-glucan test WAKO (GT). We retrospectively analysed plasma samples collected from 1289 patients at Kyoto University Hospital. IFD diagnoses were based on the European Organization for Research and Treatment of Cancer/Mycoses Study Group criteria, excluding BDG. Forty-one patients had confirmed IFDs (22 with invasive candidiasis, 11 with invasive aspergillosis, 6 with Pneumocystis pneumonia, and 2 with other IFDs). The area under the receiver operating characteristic (AUROC) of the M30 assay was 0.892 (95% confidence interval [CI], 0.836–0.949). At an optimal cutoff of 6.7 pg/ml, its sensitivity was 0.732 (95% CI, 0.571–0.858), specificity was 0.990 (95% CI, 0.889–0.922), positive predictive value was 0.204 (95% CI, 0.142–0.278), and negative predictive value was 0.990 (95% CI, 0.983–0.995). For a subset of 537 samples, comparative analysis between M30 and GT was performed. The AUROC for the M30 and GT assays was 0.899 and 0.868, respectively (P = .285). At a cutoff of 11.0 pg/ml, the sensitivity was 72.2% for both assays, and the specificity was 93.5% vs. 93.3% (P = 1.000). The M30 assay demonstrated comparable diagnostic performance to the GT assay, with a shorter assay time that may facilitate earlier clinical decision-making in patients with suspected IFD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory Medicine, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan.
- Microbiology Laboratory, Department of Clinical Laboratory, Kyoto University Hospital, Kyoto 606-8507, Japan.
ORCID-Profile: Yasuhiro Tsuchido, Yasufumi Matsumura, Koh Shinohara, Masaki Yamamoto, Miki Nagao
Förderung
- Fujifilm Wako Pure Chemical Corporation
Zitieren
APA
Tsuchido, Y., Mori, K., Matsumura, Y., Tsuda, Y., Shinohara, K., Yamamoto, M., & Nagao, M. (2025). Diagnostic accuracy of a novel blood (1→3)-β-D-glucan colourimetric assay for invasive fungal diseases: The β-glucan single M30 test WAKO. Medical Mycology. https://doi.org/10.1093/mmy/myaf105
Vancouver
Tsuchido Y, Mori K, Matsumura Y, Tsuda Y, Shinohara K, Yamamoto M, et al. Diagnostic accuracy of a novel blood (1→3)-β-D-glucan colourimetric assay for invasive fungal diseases: The β-glucan single M30 test WAKO. Medical Mycology. 2025. doi:10.1093/mmy/myaf105
BibTeX
@article{Tsuchido2025,
author = {Tsuchido, Yasuhiro and Mori, Keiichiro and Matsumura, Yasufumi and Tsuda, Yusuke and Shinohara, Koh and Yamamoto, Masaki and Nagao, Miki},
title = {Diagnostic accuracy of a novel blood (1→3)-β-D-glucan colourimetric assay for invasive fungal diseases: The β-glucan single M30 test WAKO},
journal = {Medical Mycology},
year = {2025},
doi = {10.1093/mmy/myaf105}
}
EUVIMED